Phase I/II study of temozolomide and Gleevec (imatinib mesylate [imatinib], formerly known as STI571) in advanced melanoma

Trial Profile

Phase I/II study of temozolomide and Gleevec (imatinib mesylate [imatinib], formerly known as STI571) in advanced melanoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Imatinib (Primary) ; Temozolomide (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Sep 2016 Status changed from completed to active, no longer recruiting.
    • 02 Dec 2011 Actual end date (March 2011) added as reported by ClinicalTrials.gov.
    • 02 Dec 2011 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top